Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Procainamide elicits a selective autoantibody immune response.

R L Rubin, G Reimer, E M McNally

    Clinical and Experimental Immunology
    |January 1, 1986
    PubMed
    Summary

    Procainamide therapy can trigger an autoimmune response, primarily generating antibodies against histones and denatured DNA. These drug-induced antibodies decrease after stopping procainamide treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Erysipelothrix rhusiopathiae bloodstream infection - A 22-year experience at Mayo Clinic, Minnesota.

    Zoonoses and public health·2017
    Same author

    Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.

    Drugs of today (Barcelona, Spain : 1998)·2016
    Same author

    [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].

    MMW Fortschritte der Medizin·2009
    Same author

    Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J. Immunol. 1966. 96: 464-471.

    Journal of immunology (Baltimore, Md. : 1950)·2006
    Same author

    Autoantibodies in prostate cancer.

    The New England journal of medicine·2005
    Same author

    Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.

    Clinical and experimental immunology·2003

    Area of Science:

    • Immunology
    • Pharmacology
    • Autoimmunity

    Background:

    • Procainamide is a medication known to sometimes induce autoimmune conditions.
    • Understanding the specific immune responses to procainamide is crucial for managing drug-induced autoimmunity.

    Purpose of the Study:

    • To investigate the specificity of the in vivo humoral immune response to procainamide.
    • To identify the primary autoantibodies generated during procainamide therapy.

    Main Methods:

    • Solid-phase assays
    • Immunofluorescence
    • Immunoprecipitation (including protein-A-facilitated)
    • Cytotoxicity assays
    • Absorption studies

    Main Results:

    Related Experiment Videos

    • Procainamide therapy led to increased antibodies against histones and denatured DNA.
    • These drug-induced antibody levels decreased after procainamide discontinuation.
    • Antibodies to tetanus, human IgG (rheumatoid factor), and heterologous lymphocytes remained unaffected.
    • Antinuclear antibodies were present, but absorption studies confirmed they were primarily anti-histone antibodies.
    • A subset of sera showed antibodies to ribosomal RNA or immunoprecipitated a 40kD protein.

    Conclusions:

    • Procainamide-induced autoimmunity is predominantly characterized by an immune response targeting histones and denatured DNA.
    • The observed autoimmune phenomena are specific to procainamide treatment.